Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | WRN | Q14191 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL45879 | 0.99 | MGLL (0.47) | MGLLSMN1; SMN2HPGDHTTPTGS1 | |
| SCHEMBL13401579 | 0.99 | MGLL (0.47) | MGLLSMN1; SMN2HPGDHTTPTGS1 | |
| SCHEMBL26227346 | 0.99 | MGLL (0.47) | MGLLSMN1; SMN2HPGDHTTPTGS1 | |
| SCHEMBL13311214 | 0.99 | MGLL (0.47) | MGLLSMN1; SMN2HPGDHTTPTGS1 | |
| SCHEMBL13324706 | 0.99 | MGLL (0.47) | MGLLSMN1; SMN2HPGDHTTPTGS1 | |
| SCHEMBL24621630 | 0.99 | MGLL (0.47) | MGLLSMN1; SMN2HPGDHTTPTGS1 | |
| SCHEMBL16172443 | 0.93 | MGLL (0.52) | MGLLSMN1; SMN2HPGDHTTPTGS1 | |
| SCHEMBL13226858 | 0.92 | MGLL (0.42) | MGLLSMN1; SMN2HPGDHTTPTGS1 | |
| SCHEMBL15184870 | 0.92 | TSHR (0.43) | MGLLSMN1; SMN2PTGS1PTGS2FAAH | |
| SCHEMBL13300934 | 0.92 | MGLL (0.42) | MGLLSMN1; SMN2HPGDHTTPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023201335-A2 | PURIFIED MULTIVALENT PROTEIN-HYALURONIC ACID POLYMER CONJUGATES | VALITOR, INC. (US) | 2023-10-19 | — | — | WO | disclosed |
| WO-2023201336-A2 | HUMANIZED MULTIVALENT PROTEIN CONJUGATES | VALITOR, INC. (US) | 2023-10-19 | — | — | WO | disclosed |
| US-20170274091-A1 | BENZODIAZEPINES AND CONJUGATES THEREOF | IMMUNOGEN, INC. | 2017-09-28 | — | — | US | disclosed |
| US-9732084-B2 | Pyrrolobenzodiazepines used to treat proliferative diseases | MEDIMMUNE LIMITED (GB) | 2017-08-15 | — | — | US | disclosed |
| US-9707301-B2 | Pyrrolobenzodiazepines and targeted conjugates | SEATTLE GENETICS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| WO-2017100305-A2 | COMPOSITION OF ANTIBODY CONSTRUCT-AGONIST CONJUGATES AND METHODS OF USE THEREOF | OPI VI - IP HOLDCO LLC (US) | 2017-06-15 | — | — | WO | disclosed |
| US-20170143846-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SPIROGEN LIMITED (GB) | 2017-05-25 | — | — | US | disclosed |
| US-9592240-B2 | Targeted pyrrolobenzodiazapine conjugates | SEATTLE GENETICS INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9579367-B2 | C-terminally tethered amino acids and their fibrinolytic therapeutic uses | CANADIAN BLOOD SERVICES (CA) | 2017-02-28 | — | — | US | disclosed |
| US-9567340-B2 | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases | MEDIMMUNE LIMITED (GB) | 2017-02-14 | — | — | US | disclosed |
| US-7846896-B2 | PEG conjugates of NK4 | HOFFMAN-LA ROCHE INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-7846336-B2 | regeneration of a cation exchange chromatography column for purification of polypeptides | HOFFMANN-LA ROCHE INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-20090118476-A1 | Purification of pegylated polypeptides | HOFFMANN-LA ROCHE INC. | 2009-05-07 | — | — | US | disclosed |
| US-20090101585-A1 | regeneration of a cation exchange chromatography column for purification of polypeptides | HOFFMANN-LA ROCHE INC. | 2009-04-23 | — | — | US | disclosed |
| US-7459436-B2 | Treatment of disturbances of iron distribution | HOFFMANN-LA ROCHE INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459429-B2 | Method of treating disturbances of iron distribution in inflammatory intestinal diseases | HOFFMANN-LA ROCHE INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459435-B2 | Treatment of disturbances of iron distribution | HOFFMANN-LA ROCHE INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20080085857-A1 | conjugate consisting essentially of a NK4 molecule and a polyethylene glycol group having a molecular weight of from about 20 to about 40 kDa. The invention also provides a composition in which the monoPEGylated conjugates comprise at least 90% of the total of pegylated NK4 molecules and unpegylated NK4 | BRANDT MICHAEL | 2008-04-10 | — | — | US | disclosed |
| US-7202208-B2 | Erythropoietin composition | HOFFMAN-LA ROCHE INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7169754-B2 | Erythropoietin composition | HOFFMANN-LA ROCHE INC. (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170143846-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | QDPR, SBDS, DNPEP | MGLL 4647/4885SMN1; SMN2 3366/4885HPGD 992/4885 |
| US-20170274091-A1 | BENZODIAZEPINES AND CONJUGATES THEREOF | GABBR1, GABRA1, GABBR2 | MGLL 4848/4885SMN1; SMN2 1790/4885HPGD 516/4885 |
| US-20090118476-A1 | Purification of pegylated polypeptides | EPOR, HAMP, EGFR | MGLL 2152/4885SMN1; SMN2 4575/4885HPGD 2602/4885 |
| US-20080085857-A1 | conjugate consisting essentially of a NK4 molecule and a polyethylene glycol group having a molecular weight of from about 20 to about 40 kDa. The invention also provides a composition in which the monoPEGylated conjugates comprise at least 90% of the total of pegylated NK4 molecules and unpegylated NK4 | PBK, IL4, CD47 | MGLL 1850/4885SMN1; SMN2 4743/4885HPGD 2892/4885 |
| US-20090101585-A1 | regeneration of a cation exchange chromatography column for purification of polypeptides | IAPP, HDGF, HGF | MGLL 3689/4885SMN1; SMN2 816/4885HPGD 4036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.